Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 11/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861975 | 0.85 | S1PR1 (0.39) | MAOAMAOBPDE3BPDE3APKM | |
| SCHEMBL31667447 | 0.81 | AR (0.41) | MAOAMAOBARPDE3BPDE3A | |
| SCHEMBL12021472 | 0.80 | MAOA (0.39) | MAOAMAOBAR | |
| SCHEMBL13019667 | 0.80 | GABRA1 (0.41) | MAOAMAOBARTSHRMAPK1 | |
| SCHEMBL18419802 | 0.80 | NOS2 (0.51) | NOS1NOS2 | |
| SCHEMBL8237072 | 0.79 | AR (0.42) | ARPDE3BPDE3APKMTSHR | |
| SCHEMBL14012452 | 0.77 | GAA (0.49) | MAOBARNOS2 | |
| SCHEMBL24786214 | 0.77 | AR (0.41) | ARPDE3BPDE3APKMFFAR1 | |
| SCHEMBL21872614 | 0.77 | AR (0.42) | ARPDE3BPDE3APKMTSHR | |
| SCHEMBL16954724 | 0.77 | AR (0.41) | MAOAARPDE3BPDE3APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | MAOA 1416/4885MAOB 1474/4885AR 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.